<?xml version="1.0" encoding="UTF-8"?>
<p id="Par2">The global hepatitis C virus (HCV) and human immunodeficiency virus (HIV) pandemics affect 71 and 36.9 million people, respectively, who are chronically infected worldwide
 <sup>
  <xref ref-type="bibr" rid="CR1">1</xref>,
  <xref ref-type="bibr" rid="CR2">2</xref>
 </sup>. Chronic HCV infection damages the liver over the course of decades, putting HCV patients at higher risk for developing cirrhosis and hepatocellular carcinoma
 <sup>
  <xref ref-type="bibr" rid="CR3">3</xref>
 </sup>. The clinical consequences of HCV infection are mitigated by treatment with direct acting antivirals (DAAs), which have cured more than 3 million people since 2015
 <sup>
  <xref ref-type="bibr" rid="CR4">4</xref>
 </sup>. Therefore, screening to identify positive patients in need of treatment is a critical first step towards HCV elimination. Likewise, the suppression of HIV achieved by antiretroviral therapy (ART) reduces the impact of HIV infection on CD4 T cell counts and improves life expectancy
 <sup>
  <xref ref-type="bibr" rid="CR2">2</xref>
 </sup>. Once on ART, HIV patients are less likely to transmit the virus, making HIV diagnostic testing and treatment the central pillars of HIV control efforts
 <sup>
  <xref ref-type="bibr" rid="CR5">5</xref>
 </sup>.
</p>
